[go: up one dir, main page]

TNSN05249A1 - Benzopyrannes utiles pour le traitement d'etats inflammatoires - Google Patents

Benzopyrannes utiles pour le traitement d'etats inflammatoires

Info

Publication number
TNSN05249A1
TNSN05249A1 TNP2005000249A TNSN05249A TNSN05249A1 TN SN05249 A1 TNSN05249 A1 TN SN05249A1 TN P2005000249 A TNP2005000249 A TN P2005000249A TN SN05249 A TNSN05249 A TN SN05249A TN SN05249 A1 TNSN05249 A1 TN SN05249A1
Authority
TN
Tunisia
Prior art keywords
treatment
inflammatory conditions
useful
benzopyrans
benzopyrans useful
Prior art date
Application number
TNP2005000249A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN05249A1 publication Critical patent/TNSN05249A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention concerne des méthodes et composés qui sont utiles dans le traitement d'une affection associée à des troubles à médiation par la cyclooxygénase-2. Des composés particulièrement intéressants sont des benzopyrannes et leurs analogues définis par la formule (I) dans laquelle Z, X, R1, R2, R3 et R4 répondent aux définitions figurant dans le présent mémoire.
TNP2005000249A 2003-03-31 2005-09-30 Benzopyrannes utiles pour le traitement d'etats inflammatoires TNSN05249A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45921503P 2003-03-31 2003-03-31
PCT/IB2004/001113 WO2004087686A2 (fr) 2003-03-31 2004-03-26 Composes benzopyraniques utilisables dans le traitement des pathologies inflammatoires

Publications (1)

Publication Number Publication Date
TNSN05249A1 true TNSN05249A1 (fr) 2007-06-11

Family

ID=33131871

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000249A TNSN05249A1 (fr) 2003-03-31 2005-09-30 Benzopyrannes utiles pour le traitement d'etats inflammatoires

Country Status (25)

Country Link
US (1) US7259266B2 (fr)
EP (1) EP1615905A2 (fr)
JP (1) JP2006522098A (fr)
KR (1) KR20060015490A (fr)
CN (1) CN1768050A (fr)
AR (1) AR044207A1 (fr)
AU (1) AU2004226164A1 (fr)
BR (1) BRPI0408388A (fr)
CA (1) CA2520724A1 (fr)
EA (1) EA200501399A1 (fr)
EC (2) ECSP056064A (fr)
IS (1) IS7995A (fr)
MA (1) MA27725A1 (fr)
MX (1) MXPA05010630A (fr)
NL (9) NL1025843C2 (fr)
NO (1) NO20054121L (fr)
OA (1) OA13112A (fr)
PA (1) PA8599601A1 (fr)
PE (1) PE20050012A1 (fr)
RS (1) RS20050744A (fr)
TN (1) TNSN05249A1 (fr)
TW (1) TWI257927B (fr)
UY (1) UY28252A1 (fr)
WO (1) WO2004087686A2 (fr)
ZA (1) ZA200506551B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CA2574363A1 (fr) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Methode enantioselective pour la separation de derives d'acide 2-trifluoromethyl-2h-chromene-3-carboxylique
WO2006011052A1 (fr) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Procede de racemisation d'acides carboxyliques 2-trifluoro-2h-chromene-3
EP1778662A1 (fr) * 2004-07-23 2007-05-02 Warner-Lambert Company LLC Photoracemisation de derives de l' acide 2-trifluoromethyl-2h-chromene-3-carboxylique
EP1792887A1 (fr) * 2005-12-05 2007-06-06 Laboratorios Del Dr. Esteve, S.A. Procédé pour l'hydrogénation homogène de cétones utilisant catalyseurs à base de ruthénium
WO2009079011A1 (fr) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles et analogues comme inhibiteurs de la rho-kinase
JP2011507850A (ja) * 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
EP2234618A4 (fr) * 2007-12-21 2011-04-27 Scripps Research Inst Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase
CN102757417B (zh) * 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
EP2860177A3 (fr) * 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthèse d'arènes fonctionnalisés
EP3052482A1 (fr) * 2013-09-30 2016-08-10 Polfarmex S.A. Nouveaux n,n-diméthylaminoalkyléthers substitués d'oximes d'isoflavanone utilisés comme antagonistes des récepteurs h1
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2015109013A1 (fr) * 2014-01-14 2015-07-23 Euclises Pharmaceuticals, Inc. Conjugués de nitrooxy-chromène deutéré libérant du no
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN107868069A (zh) * 2017-10-31 2018-04-03 山东新华制药股份有限公司 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺
US12521201B2 (en) 2017-12-07 2026-01-13 Augmedics Ltd. Spinous process clamp
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
US11980507B2 (en) 2018-05-02 2024-05-14 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
CN109020990A (zh) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US12502163B2 (en) 2020-09-09 2025-12-23 Augmedics Ltd. Universal tool adapter for image-guided surgery
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
US20240308988A1 (en) 2021-08-05 2024-09-19 Syngenta Crop Protection Ag Method For Controlling Diamide Resistant Pests and Compounds Therefor
US12475662B2 (en) 2021-08-18 2025-11-18 Augmedics Ltd. Stereoscopic display and digital loupe for augmented-reality near-eye display
EP4511809A1 (fr) 2022-04-21 2025-02-26 Augmedics Ltd. Systèmes et procédés de visualisation d'image médicale
IL319523A (en) 2022-09-13 2025-05-01 Augmedics Ltd Augmented reality glasses for image-guided medical intervention
CN116903457A (zh) * 2023-07-18 2023-10-20 上海添泽生物医药有限公司 一种2-羟基-5-异丙基苯甲酸的合成方法
CN119285593B (zh) * 2024-10-08 2025-09-23 河南农业大学 苯并吡喃类衍生物、合成方法及应用
CN119954759B (zh) * 2025-01-03 2025-10-21 安炎达医药技术(广州)有限公司 一种苯并吡喃类cox-2抑制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20030153801A1 (en) 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
US6620871B2 (en) * 2001-06-07 2003-09-16 Nike, Inc. Rubber compositions with increased shelf life and reduced cure temperatures and times
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor

Also Published As

Publication number Publication date
NL1028310C2 (nl) 2005-11-16
BRPI0408388A (pt) 2006-03-01
KR20060015490A (ko) 2006-02-17
NL1028309C2 (nl) 2005-11-16
AU2004226164A1 (en) 2004-10-14
JP2006522098A (ja) 2006-09-28
OA13112A (en) 2006-11-10
NL1028305C2 (nl) 2005-11-16
NL1028310A1 (nl) 2005-03-09
AR044207A1 (es) 2005-09-07
ECSP056063A (es) 2006-01-27
WO2004087686A3 (fr) 2004-12-16
NL1028303A1 (nl) 2005-03-09
WO2004087686A2 (fr) 2004-10-14
PA8599601A1 (es) 2005-05-24
NL1028309A1 (nl) 2005-03-09
NL1028308A1 (nl) 2005-03-09
RS20050744A (sr) 2007-08-03
NL1025843A1 (nl) 2004-10-01
NO20054121L (no) 2005-12-20
NL1028306C2 (nl) 2005-11-16
MA27725A1 (fr) 2006-01-02
CA2520724A1 (fr) 2004-10-14
EP1615905A2 (fr) 2006-01-18
NL1025843C2 (nl) 2005-03-01
IS7995A (is) 2005-08-18
UY28252A1 (es) 2004-11-08
CN1768050A (zh) 2006-05-03
EA200501399A1 (ru) 2006-04-28
MXPA05010630A (es) 2005-12-12
NL1028304A1 (nl) 2005-03-09
US20050148777A1 (en) 2005-07-07
PE20050012A1 (es) 2005-03-12
ZA200506551B (en) 2006-11-29
NL1028304C2 (nl) 2005-11-16
NL1028307A1 (nl) 2005-03-09
NL1028308C2 (nl) 2005-11-16
TW200510365A (en) 2005-03-16
NO20054121D0 (no) 2005-09-05
US7259266B2 (en) 2007-08-21
TWI257927B (en) 2006-07-11
NL1028307C2 (nl) 2005-11-16
NL1028305A1 (nl) 2005-03-09
NL1028303C2 (nl) 2005-11-16
ECSP056064A (es) 2006-01-27
NL1028306A1 (nl) 2005-03-09

Similar Documents

Publication Publication Date Title
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA29870B1 (fr) Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
MA29289B1 (fr) Composes bis aryles et heteroaryles substitues en tant qu'antagonistes selectifs de 5ht2a
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
TNSN06386A1 (fr) Derives de tetraazabenzo [e] azulene et leurs analogues
DE60217186D1 (de) Dpiv-inhibitoren auf glutaminbasis
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
ATE368031T1 (de) Neue gamma secretase inhibitoren
CY1106969T1 (el) Αναστολεις dpp-iv
SE0403006D0 (sv) New compounds
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
TNSN08196A1 (fr) Derives de pyrazine
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
DK1670903T3 (da) Behandling af neurodegenerative sygdomme